Basic Information
| LncRNA/CircRNA Name | LINC00675 |
| Synonyms | NORAD, LINC00657, ASHGA5P032173 |
| Region | GRCh38_20:36045622-36050960 |
| Ensemble | ENSG00000260032 |
| Refseq | NR_027451 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic ductal adenocarcinoma |
| ICD-0-3 | C25.3 |
| Methods | Microarray, qPCR, RNAi, Western blot etc. |
| Sample | PDAC tissues, cell lines (cell lines PANC1, Capan2, BXPC-3, Mia PaCa2, SW1990) |
| Expression Pattern | up-regulated |
| Function Description | The expression of Linc00675 in PDAC tissue samples was shown to be 672 times that in chronic pancreatitis tissue samples by microarray screening. This finding was confirmed in tumor tissues from 90 patients with PDAC compared with adjacent normal tissue samples by quantitative RT-PCR. We found that linc00675 overexpression positively correlated with lymph node metastasis, perineural invasion, and poor survival. |
| Pubmed ID | 26309360 |
| Year | 2015 |
| Title | Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. |
External Links
| Links for LINC00675 | GenBank HGNC NONCODE |
| Links for pancreatic ductal adenocarcinoma | OMIM COSMIC |